Brian C. Broderick’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$477K Hold
3,121
0.09% 74
2025
Q4
$430K Hold
3,121
0.08% 70
2025
Q3
$400K Sell
3,121
-1,082
-26% -$132K 0.08% 73
2025
Q2
$509K Sell
4,203
-70
-2% -$7.89K 0.1% 68
2025
Q1
$476K Sell
4,273
-3,800
-47% -$405K 0.1% 69
2024
Q4
$786K Sell
8,073
-3,960
-33% -$422K 0.15% 57
2024
Q3
$1.38M Sell
12,033
-6,780
-36% -$769K 0.27% 52
2024
Q2
$2M Sell
18,813
-3,021
-14% -$303K 0.41% 46
2024
Q1
$2.11M Sell
21,834
-6,126
-22% -$628K 0.45% 41
2023
Q4
$2.82M Sell
27,960
-1,055
-4% -$102K 0.7% 37
2023
Q3
$2.96M Buy
29,015
+1,425
+5% +$145K 0.81% 36
2023
Q2
$2.78M Sell
27,590
-360
-1% -$36K 0.73% 37
2023
Q1
$2.57M Sell
27,950
-525
-2% -$45.9K 0.72% 38
2022
Q4
$2.58M Sell
28,475
-1,930
-6% -$163K 0.77% 37
2022
Q3
$2.31M Sell
30,405
-1,980
-6% -$164K 0.72% 40
2022
Q2
$2.74M Sell
32,385
-3,848
-11% -$338K 0.83% 39
2022
Q1
$3.18M Sell
36,233
-4,867
-12% -$421K 0.81% 38
2021
Q4
$3.6M Sell
41,100
-27,295
-40% -$2.27M 0.86% 38
2021
Q3
$5.59M Sell
68,395
-12,109
-15% -$1.09M 1.49% 27
2021
Q2
$7.34M Sell
80,504
-4,869
-6% -$434K 1.95% 21
2021
Q1
$7.3M Sell
85,373
-847
-1% -$76K 2.1% 20
2020
Q4
$8.14M Sell
86,220
-425
-0.5% -$37.1K 2.42% 18
2020
Q3
$7.54M Buy
86,645
+941
+1% +$81.5K 2.4% 17
2020
Q2
$7.49M Sell
85,704
-683
-0.8% -$59K 2.49% 16
2020
Q1
$7.12M Buy
86,387
+212
+0.2% +$18.9K 2.82% 12
2019
Q4
$8.16M Sell
86,175
-627
-0.7% -$56.3K 2.64% 15
2019
Q3
$7.54M Sell
86,802
-663
-0.8% -$59.5K 2.59% 15
2019
Q2
$7.99M Sell
87,465
-10,291
-11% -$871K 2.79% 12
2019
Q1
$8.42M Sell
97,756
-1,710
-2% -$137K 3.01% 10
2018
Q4
$7.65M Sell
99,466
-2,680
-3% -$209K 3.22% 6
2018
Q3
$7.89M Buy
102,146
+292
+0.3% +$21.6K 2.68% 13
2018
Q2
$6.89M Buy
101,854
+1,138
+1% +$78.5K 2.52% 16
2018
Q1
$7.3M Buy
100,716
+47
+0% +$3.58K 2.74% 14
2017
Q4
$7.57M Sell
100,669
-4,499
-4% -$339K 2.76% 11
2017
Q3
$8.09M Buy
105,168
+1,883
+2% +$142K 2.92% 9
2017
Q2
$7.73M Buy
103,285
+2,132
+2% +$151K 2.86% 9
2017
Q1
$6.73M Buy
101,153
+2,213
+2% +$147K 2.75% 11
2016
Q4
$6.46M Sell
98,940
-536
-0.5% -$34.8K 2.8% 11
2016
Q3
$7.04M Sell
99,476
-1,551
-2% -$113K 3% 10
2016
Q2
$7.47M Buy
101,027
+3,566
+4% +$246K 3.14% 9
2016
Q1
$6.33M Buy
97,461
+7,175
+8% +$488K 2.74% 11
2015
Q4
$6.96M Sell
90,286
-120
-0.1% -$9.53K 3.11% 8
2015
Q3
$7.45M Buy
90,406
+212
+0.2% +$18.9K 3.45% 4
2015
Q2
$7.95M Sell
90,194
-1,351
-1% -$124K 3.39% 3
2015
Q1
$8.09M Buy
91,545
+736
+0.8% +$65.3K 3.36% 5
2014
Q4
$7.54M Buy
90,809
+6,054
+7% +$502K 3.19% 6
2014
Q3
$7.15M Buy
84,755
+660
+0.8% +$53.4K 3.18% 4
2014
Q2
$6.82M Buy
84,095
+2,461
+3% +$194K 3.12% 4
2014
Q1
$6.22M Buy
81,634
+11
+0% +$802 3.06% 6
2013
Q4
$5.88M Sell
81,623
-558
-0.7% -$38.8K 2.93% 11
2013
Q3
$5.65M Sell
82,181
-28
-0% -$1.85K 3.15% 8
2013
Q2
$5.21M Buy
+82,209
New +$5.35M 3.12% 7

Other funds holding NVS

Brian C. Broderick's NVS Position: Q1 2026 in Review

Brian C. Broderick held its Novartis (NVS) position steady in Q1 2026 at 3,121 shares worth $477K. The position accounts for 0.09% of the portfolio, ranked #74.

Brian C. Broderick first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.42M in Q1 2019. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Brian C. Broderick held 3,121 shares of Novartis worth $477K as of Q1 2026.
  • Brian C. Broderick left its Novartis share count unchanged in Q1 2026.
  • Novartis made up 0.09% of Brian C. Broderick's portfolio in Q1 2026, its #74 holding.
  • Brian C. Broderick first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • Brian C. Broderick's Novartis position peaked at $8.42M in Q1 2019.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Brian C. Broderick's 13F filing for Q1 2026, filed 7 May 2026.